Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Intensive care unit physician staffing: financial modeling of the Leapfrog standard.

Critical care medicine

Pronovost PJ, Needham DM, Waters H, Birkmeyer CM, Calinawan JR, Birkmeyer JD, Dorman T.
PMID: 16477199
Crit Care Med. 2006 Mar;34(3):S18-24. doi: 10.1097/01.CCM.0000208369.12812.92.

OBJECTIVE: To evaluate from a hospital's perspective the costs and savings, over a 1-yr period, of implementing The Leapfrog Group's Intensive Care Unit Physician Staffing (IPS) standard compared with the existing standard of nonintensivist staffing in adult intensive care...

Cite
Pronovost PJ, Needham DM, Waters H, et al. Intensive care unit physician staffing: financial modeling of the Leapfrog standard. Crit Care Med. 2006;34(3):S18-24doi: 10.1097/01.CCM.0000208369.12812.92.
Pronovost, P. J., Needham, D. M., Waters, H., Birkmeyer, C. M., Calinawan, J. R., Birkmeyer, J. D., & Dorman, T. (2006). Intensive care unit physician staffing: financial modeling of the Leapfrog standard. Critical care medicine, 34(3), S18-24. https://doi.org/10.1097/01.CCM.0000208369.12812.92
Pronovost, Peter J, et al. "Intensive care unit physician staffing: financial modeling of the Leapfrog standard." Critical care medicine vol. 34,3 (2006): S18-24. doi: https://doi.org/10.1097/01.CCM.0000208369.12812.92
Pronovost PJ, Needham DM, Waters H, Birkmeyer CM, Calinawan JR, Birkmeyer JD, Dorman T. Intensive care unit physician staffing: financial modeling of the Leapfrog standard. Crit Care Med. 2006 Mar;34(3):S18-24. doi: 10.1097/01.CCM.0000208369.12812.92. PMID: 16477199.
Copy Download .nbib Format: NLM
Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.

Cell reports. Medicine

Huang D, Chowdhury S, Wang H, Savage SR, Ivey RG, Kennedy JJ, Whiteaker JR, Lin C, Hou X, Oberg AL, Larson MC, Eskandari N, Delisi DA, Gentile S, Huntoon CJ, Voytovich UJ, Shire ZJ, Yu Q, Gygi SP, Hoofnagle AN, Herbert ZT, Lorentzen TD, Calinawan A, Karnitz LM, Weroha SJ, Kaufmann SH, Zhang B, Wang P, Birrer MJ, Paulovich AG.
PMID: 35028612
Cell Rep Med. 2021 Dec 21;2(12):100471. doi: 10.1016/j.xcrm.2021.100471. eCollection 2021 Dec 21.

Resistance to platinum compounds is a major determinant of patient survival in high-grade serous ovarian cancer (HGSOC). To understand mechanisms of platinum resistance and identify potential therapeutic targets in resistant HGSOC, we generated a data resource composed of dynamic...

Cite
Huang D, Chowdhury S, Wang H, et al. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell Rep Med. 2021;2(12):100471doi: 10.1016/j.xcrm.2021.100471.
Huang, D., Chowdhury, S., Wang, H., Savage, S. R., Ivey, R. G., Kennedy, J. J., Whiteaker, J. R., Lin, C., Hou, X., Oberg, A. L., Larson, M. C., Eskandari, N., Delisi, D. A., Gentile, S., Huntoon, C. J., Voytovich, U. J., Shire, Z. J., Yu, Q., Gygi, S. P., Hoofnagle, A. N., Herbert, Z. T., Lorentzen, T. D., Calinawan, A., Karnitz, L. M., Weroha, S. J., Kaufmann, S. H., Zhang, B., Wang, P., Birrer, M. J., & Paulovich, A. G. (2021). Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell reports. Medicine, 2(12), 100471. https://doi.org/10.1016/j.xcrm.2021.100471
Huang, Dongqing, et al. "Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer." Cell reports. Medicine vol. 2,12 (2021): 100471. doi: https://doi.org/10.1016/j.xcrm.2021.100471
Huang D, Chowdhury S, Wang H, Savage SR, Ivey RG, Kennedy JJ, Whiteaker JR, Lin C, Hou X, Oberg AL, Larson MC, Eskandari N, Delisi DA, Gentile S, Huntoon CJ, Voytovich UJ, Shire ZJ, Yu Q, Gygi SP, Hoofnagle AN, Herbert ZT, Lorentzen TD, Calinawan A, Karnitz LM, Weroha SJ, Kaufmann SH, Zhang B, Wang P, Birrer MJ, Paulovich AG. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell Rep Med. 2021 Dec 21;2(12):100471. doi: 10.1016/j.xcrm.2021.100471. eCollection 2021 Dec 21. PMID: 35028612; PMCID: PMC8714940.
Copy Download .nbib Format: NLM
A highly annotated database of genes associated with platinum resistance in cancer.

Oncogene

Huang D, Savage SR, Calinawan AP, Lin C, Zhang B, Wang P, Starr TK, Birrer MJ, Paulovich AG.
PMID: 34645978
Oncogene. 2021 Nov;40(46):6395-6405. doi: 10.1038/s41388-021-02055-2. Epub 2021 Oct 13.

Platinum-based chemotherapy, including cisplatin, carboplatin, and oxaliplatin, is prescribed to 10-20% of all cancer patients. Unfortunately, platinum resistance develops in a significant number of patients and is a determinant of clinical outcome. Extensive research has been conducted to understand...

Cite
Huang D, Savage SR, Calinawan AP, et al. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene. 2021;40(46):6395-6405doi: 10.1038/s41388-021-02055-2.
Huang, D., Savage, S. R., Calinawan, A. P., Lin, C., Zhang, B., Wang, P., Starr, T. K., Birrer, M. J., & Paulovich, A. G. (2021). A highly annotated database of genes associated with platinum resistance in cancer. Oncogene, 40(46), 6395-6405. https://doi.org/10.1038/s41388-021-02055-2
Huang, Dongqing, et al. "A highly annotated database of genes associated with platinum resistance in cancer." Oncogene vol. 40,46 (2021): 6395-6405. doi: https://doi.org/10.1038/s41388-021-02055-2
Huang D, Savage SR, Calinawan AP, Lin C, Zhang B, Wang P, Starr TK, Birrer MJ, Paulovich AG. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene. 2021 Nov;40(46):6395-6405. doi: 10.1038/s41388-021-02055-2. Epub 2021 Oct 13. PMID: 34645978; PMCID: PMC8602037.
Copy Download .nbib Format: NLM
Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.

Cell reports. Medicine

Huang D, Chowdhury S, Wang H, Savage SR, Ivey RG, Kennedy JJ, Whiteaker JR, Lin C, Hou X, Oberg AL, Larson MC, Eskandari N, Delisi DA, Gentile S, Huntoon CJ, Voytovich UJ, Shire ZJ, Yu Q, Gygi SP, Hoofnagle AN, Herbert ZT, Lorentzen TD, Calinawan A, Karnitz LM, Weroha SJ, Kaufmann SH, Zhang B, Wang P, Birrer MJ, Paulovich AG.
PMID: 35028612
Cell Rep Med. 2021 Dec 21;2(12):100471. doi: 10.1016/j.xcrm.2021.100471. eCollection 2021 Dec 21.

Resistance to platinum compounds is a major determinant of patient survival in high-grade serous ovarian cancer (HGSOC). To understand mechanisms of platinum resistance and identify potential therapeutic targets in resistant HGSOC, we generated a data resource composed of dynamic...

Cite
Huang D, Chowdhury S, Wang H, et al. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell Rep Med. 2021;2(12):100471doi: 10.1016/j.xcrm.2021.100471.
Huang, D., Chowdhury, S., Wang, H., Savage, S. R., Ivey, R. G., Kennedy, J. J., Whiteaker, J. R., Lin, C., Hou, X., Oberg, A. L., Larson, M. C., Eskandari, N., Delisi, D. A., Gentile, S., Huntoon, C. J., Voytovich, U. J., Shire, Z. J., Yu, Q., Gygi, S. P., Hoofnagle, A. N., Herbert, Z. T., Lorentzen, T. D., Calinawan, A., Karnitz, L. M., Weroha, S. J., Kaufmann, S. H., Zhang, B., Wang, P., Birrer, M. J., & Paulovich, A. G. (2021). Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell reports. Medicine, 2(12), 100471. https://doi.org/10.1016/j.xcrm.2021.100471
Huang, Dongqing, et al. "Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer." Cell reports. Medicine vol. 2,12 (2021): 100471. doi: https://doi.org/10.1016/j.xcrm.2021.100471
Huang D, Chowdhury S, Wang H, Savage SR, Ivey RG, Kennedy JJ, Whiteaker JR, Lin C, Hou X, Oberg AL, Larson MC, Eskandari N, Delisi DA, Gentile S, Huntoon CJ, Voytovich UJ, Shire ZJ, Yu Q, Gygi SP, Hoofnagle AN, Herbert ZT, Lorentzen TD, Calinawan A, Karnitz LM, Weroha SJ, Kaufmann SH, Zhang B, Wang P, Birrer MJ, Paulovich AG. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell Rep Med. 2021 Dec 21;2(12):100471. doi: 10.1016/j.xcrm.2021.100471. eCollection 2021 Dec 21. PMID: 35028612; PMCID: PMC8714940.
Copy Download .nbib Format: NLM
Post-anticoagulant D-dimer is a highly prognostic biomarker of COVID-19 mortality.

ERJ open research

Song X, Ji J, Reva B, Joshi H, Calinawan AP, Mazumdar M, Wisnivesky JP, Taioli E, Wang P, Veluswamy RR.
PMID: 34230883
ERJ Open Res. 2021 Jul 05;7(3). doi: 10.1183/23120541.00018-2021. eCollection 2021 Jul.

Clinical biomarkers that accurately predict mortality are needed for the effective management of patients with severe coronavirus disease 2019 (COVID-19) illness. In this study, we determine whether changes in D-dimer levels after anticoagulation are independently predictive of in-hospital mortality....

Cite
Song X, Ji J, Reva B, et al. Post-anticoagulant D-dimer is a highly prognostic biomarker of COVID-19 mortality. ERJ Open Res. 2021;7(3)doi: 10.1183/23120541.00018-2021.
Song, X., Ji, J., Reva, B., Joshi, H., Calinawan, A. P., Mazumdar, M., Wisnivesky, J. P., Taioli, E., Wang, P., & Veluswamy, R. R. (2021). Post-anticoagulant D-dimer is a highly prognostic biomarker of COVID-19 mortality. ERJ open research, 7(3), . https://doi.org/10.1183/23120541.00018-2021
Song, Xiaoyu, et al. "Post-anticoagulant D-dimer is a highly prognostic biomarker of COVID-19 mortality." ERJ open research vol. 7,3 (2021). doi: https://doi.org/10.1183/23120541.00018-2021
Song X, Ji J, Reva B, Joshi H, Calinawan AP, Mazumdar M, Wisnivesky JP, Taioli E, Wang P, Veluswamy RR. Post-anticoagulant D-dimer is a highly prognostic biomarker of COVID-19 mortality. ERJ Open Res. 2021 Jul 05;7(3). doi: 10.1183/23120541.00018-2021. eCollection 2021 Jul. PMID: 34230883; PMCID: PMC7942219.
Copy Download .nbib Format: NLM
A highly annotated database of genes associated with platinum resistance in cancer.

Oncogene

Huang D, Savage SR, Calinawan AP, Lin C, Zhang B, Wang P, Starr TK, Birrer MJ, Paulovich AG.
PMID: 34645978
Oncogene. 2021 Nov;40(46):6395-6405. doi: 10.1038/s41388-021-02055-2. Epub 2021 Oct 13.

Platinum-based chemotherapy, including cisplatin, carboplatin, and oxaliplatin, is prescribed to 10-20% of all cancer patients. Unfortunately, platinum resistance develops in a significant number of patients and is a determinant of clinical outcome. Extensive research has been conducted to understand...

Cite
Huang D, Savage SR, Calinawan AP, et al. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene. 2021;40(46):6395-6405doi: 10.1038/s41388-021-02055-2.
Huang, D., Savage, S. R., Calinawan, A. P., Lin, C., Zhang, B., Wang, P., Starr, T. K., Birrer, M. J., & Paulovich, A. G. (2021). A highly annotated database of genes associated with platinum resistance in cancer. Oncogene, 40(46), 6395-6405. https://doi.org/10.1038/s41388-021-02055-2
Huang, Dongqing, et al. "A highly annotated database of genes associated with platinum resistance in cancer." Oncogene vol. 40,46 (2021): 6395-6405. doi: https://doi.org/10.1038/s41388-021-02055-2
Huang D, Savage SR, Calinawan AP, Lin C, Zhang B, Wang P, Starr TK, Birrer MJ, Paulovich AG. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene. 2021 Nov;40(46):6395-6405. doi: 10.1038/s41388-021-02055-2. Epub 2021 Oct 13. PMID: 34645978; PMCID: PMC8602037.
Copy Download .nbib Format: NLM
Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.

Cell

Clark DJ, Dhanasekaran SM, Petralia F, Pan J, Song X, Hu Y, da Veiga Leprevost F, Reva B, Lih TM, Chang HY, Ma W, Huang C, Ricketts CJ, Chen L, Krek A, Li Y, Rykunov D, Li QK, Chen LS, Ozbek U, Vasaikar S, Wu Y, Yoo S, Chowdhury S, Wyczalkowski MA, Ji J, Schnaubelt M, Kong A, Sethuraman S, Avtonomov DM, Ao M, Colaprico A, Cao S, Cho KC, Kalayci S, Ma S, Liu W, Ruggles K, Calinawan A, Gümüş ZH, Geiszler D, Kawaler E, Teo GC, Wen B, Zhang Y, Keegan S, Li K, Chen F, Edwards N, Pierorazio PM, Chen XS, Pavlovich CP, Hakimi AA, Brominski G, Hsieh JJ, Antczak A, Omelchenko T, Lubinski J, Wiznerowicz M, Linehan WM, Kinsinger CR, Thiagarajan M, Boja ES, Mesri M, Hiltke T, Robles AI, Rodriguez H, Qian J, Fenyö D, Zhang B, Ding L, Schadt E, Chinnaiyan AM, Zhang Z, Omenn GS, Cieslik M, Chan DW, Nesvizhskii AI, Wang P, Zhang H.
PMID: 31923397
Cell. 2020 Jan 09;180(1):207. doi: 10.1016/j.cell.2019.12.026.

No abstract available.

Cite
Clark DJ, Dhanasekaran SM, Petralia F, et al. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell. 2020;180(1):207doi: 10.1016/j.cell.2019.12.026.
Clark, D. J., Dhanasekaran, S. M., Petralia, F., Pan, J., Song, X., Hu, Y., da Veiga Leprevost, F., Reva, B., Lih, T. M., Chang, H. Y., Ma, W., Huang, C., Ricketts, C. J., Chen, L., Krek, A., Li, Y., Rykunov, D., Li, Q. K., Chen, L. S., Ozbek, U., Vasaikar, S., Wu, Y., Yoo, S., Chowdhury, S., Wyczalkowski, M. A., Ji, J., Schnaubelt, M., Kong, A., Sethuraman, S., Avtonomov, D. M., Ao, M., Colaprico, A., Cao, S., Cho, K. C., Kalayci, S., Ma, S., Liu, W., Ruggles, K., Calinawan, A., Gümüş, Z. H., Geiszler, D., Kawaler, E., Teo, G. C., Wen, B., Zhang, Y., Keegan, S., Li, K., Chen, F., Edwards, N., Pierorazio, P. M., Chen, X. S., Pavlovich, C. P., Hakimi, A. A., Brominski, G., Hsieh, J. J., Antczak, A., Omelchenko, T., Lubinski, J., Wiznerowicz, M., Linehan, W. M., Kinsinger, C. R., Thiagarajan, M., Boja, E. S., Mesri, M., Hiltke, T., Robles, A. I., Rodriguez, H., Qian, J., Fenyö, D., Zhang, B., Ding, L., Schadt, E., Chinnaiyan, A. M., Zhang, Z., Omenn, G. S., Cieslik, M., Chan, D. W., Nesvizhskii, A. I., Wang, P., Zhang, H. (2020). Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell, 180(1), 207. https://doi.org/10.1016/j.cell.2019.12.026
Clark, David J, et al. "Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma." Cell vol. 180,1 (2020): 207. doi: https://doi.org/10.1016/j.cell.2019.12.026
Clark DJ, Dhanasekaran SM, Petralia F, Pan J, Song X, Hu Y, da Veiga Leprevost F, Reva B, Lih TM, Chang HY, Ma W, Huang C, Ricketts CJ, Chen L, Krek A, Li Y, Rykunov D, Li QK, Chen LS, Ozbek U, Vasaikar S, Wu Y, Yoo S, Chowdhury S, Wyczalkowski MA, Ji J, Schnaubelt M, Kong A, Sethuraman S, Avtonomov DM, Ao M, Colaprico A, Cao S, Cho KC, Kalayci S, Ma S, Liu W, Ruggles K, Calinawan A, Gümüş ZH, Geiszler D, Kawaler E, Teo GC, Wen B, Zhang Y, Keegan S, Li K, Chen F, Edwards N, Pierorazio PM, Chen XS, Pavlovich CP, Hakimi AA, Brominski G, Hsieh JJ, Antczak A, Omelchenko T, Lubinski J, Wiznerowicz M, Linehan WM, Kinsinger CR, Thiagarajan M, Boja ES, Mesri M, Hiltke T, Robles AI, Rodriguez H, Qian J, Fenyö D, Zhang B, Ding L, Schadt E, Chinnaiyan AM, Zhang Z, Omenn GS, Cieslik M, Chan DW, Nesvizhskii AI, Wang P, Zhang H. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell. 2020 Jan 09;180(1):207. doi: 10.1016/j.cell.2019.12.026. PMID: 31923397.
Copy Download .nbib Format: NLM
ProTrack: An Interactive Multi-Omics Data Browser for Proteogenomic Studies.

Proteomics

Calinawan AP, Song X, Ji J, Dhanasekaran SM, Petralia F, Wang P, Reva B.
PMID: 32510176
Proteomics. 2020 Nov;20(21):e1900359. doi: 10.1002/pmic.201900359. Epub 2020 Aug 06.

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) initiative has generated extensive multi-omics data resources of deep proteogenomic profiles for multiple cancer types. To enable the broader community of biological and medical researchers to intuitively query, explore, and download data...

Cite
Calinawan AP, Song X, Ji J, et al. ProTrack: An Interactive Multi-Omics Data Browser for Proteogenomic Studies. Proteomics. 2020;20(21):e1900359doi: 10.1002/pmic.201900359.
Calinawan, A. P., Song, X., Ji, J., Dhanasekaran, S. M., Petralia, F., Wang, P., & Reva, B. (2020). ProTrack: An Interactive Multi-Omics Data Browser for Proteogenomic Studies. Proteomics, 20(21), e1900359. https://doi.org/10.1002/pmic.201900359
Calinawan, Anna Pamela, et al. "ProTrack: An Interactive Multi-Omics Data Browser for Proteogenomic Studies." Proteomics vol. 20,21 (2020): e1900359. doi: https://doi.org/10.1002/pmic.201900359
Calinawan AP, Song X, Ji J, Dhanasekaran SM, Petralia F, Wang P, Reva B. ProTrack: An Interactive Multi-Omics Data Browser for Proteogenomic Studies. Proteomics. 2020 Nov;20(21):e1900359. doi: 10.1002/pmic.201900359. Epub 2020 Aug 06. PMID: 32510176; PMCID: PMC7677200.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries